Bruce I.  Sachs net worth and biography

Bruce Sachs Biography and Net Worth

Mr. Sachs joined our Board in 1998 and is the Board's lead independent director. Mr. Sachs is a General Partner at Charles River Ventures, a venture capital firm he joined in 1999. From 1998 to 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. From 1997 until 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer of Xylogics, Inc. Mr. Sachs holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University.

What is Bruce I. Sachs' net worth?

The estimated net worth of Bruce I. Sachs is at least $14.01 million as of November 6th, 2023. Mr. Sachs owns 40,000 shares of Vertex Pharmaceuticals stock worth more than $14,006,000 as of December 10th. This net worth estimate does not reflect any other investments that Mr. Sachs may own. Learn More about Bruce I. Sachs' net worth.

How do I contact Bruce I. Sachs?

The corporate mailing address for Mr. Sachs and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Bruce I. Sachs' contact information.

Has Bruce I. Sachs been buying or selling shares of Vertex Pharmaceuticals?

In the last ninety days, Bruce I. Sachs has sold $4,331,250.00 in shares of Vertex Pharmaceuticals stock. Most recently, Bruce I. Sachs sold 11,250 shares of the business's stock in a transaction on Monday, November 6th. The shares were sold at an average price of $385.00, for a transaction totalling $4,331,250.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company's stock, valued at $15,400,000. Learn More on Bruce I. Sachs' trading history.

Who are Vertex Pharmaceuticals' active insiders?

Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vertex Pharmaceuticals?

During the last year, insiders at the pharmaceutical company sold shares 46 times. They sold a total of 172,832 shares worth more than $58,552,908.62. The most recent insider tranaction occured on November, 6th when Director Bruce I Sachs sold 11,250 shares worth more than $4,331,250.00. Insiders at Vertex Pharmaceuticals own 0.4% of the company. Learn More about insider trades at Vertex Pharmaceuticals.

Information on this page was last updated on 11/6/2023.

Bruce I. Sachs Insider Trading History at Vertex Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2023Sell11,250$385.00$4,331,250.0040,000View SEC Filing Icon  
7/17/2023Sell11,250$356.75$4,013,437.5040,000View SEC Filing Icon  
4/12/2023Sell21,300$326.73$6,959,349.0041,210View SEC Filing Icon  
11/10/2020Buy15,000$217.36$3,260,400.0018,035View SEC Filing Icon  
5/7/2020Sell45,000$269.80$12,141,000.0033,710View SEC Filing Icon  
1/9/2015Sell9,861$125.04$1,233,019.44View SEC Filing Icon  
11/28/2014Sell10,000$120.03$1,200,300.00View SEC Filing Icon  
11/6/2014Sell9,900$115.21$1,140,579.00View SEC Filing Icon  
11/5/2014Sell30,100$112.62$3,389,862.00View SEC Filing Icon  
10/24/2013Sell8,300$77.06$639,598.00View SEC Filing Icon  
7/24/2013Sell8,300$85.50$709,650.00View SEC Filing Icon  
6/21/2013Sell8,300$75.93$630,219.00View SEC Filing Icon  
5/14/2013Sell60,000$81.15$4,869,000.00View SEC Filing Icon  
See Full Table

Bruce I. Sachs Buying and Selling Activity at Vertex Pharmaceuticals

This chart shows Bruce I Sachs's buying and selling at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $350.15
Low: $348.46
High: $354.35

50 Day Range

MA: $360.89
Low: $343.00
High: $385.76

2 Week Range

Now: $350.15
Low: $282.21
High: $387.42


1,394,568 shs

Average Volume

1,392,697 shs

Market Capitalization

$90.23 billion

P/E Ratio


Dividend Yield